Nebaprubart

奈巴扑拜单抗

Report date: 2026/04/16 20:00:17

Base Information

Drug NameNebaprubart
Drug Alias NameHuman IgG4k monoclonal antibody against CD89 (Jjp Biologics)JJP-1212JJP1212
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-IgA Fc receptor
TargetsIgA Fc receptor
Therapy Area/IndicationsLinear IgA Bullous Dermatosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPolandEU
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesJjp Biologics Sp. z o.o.
China Registration ClassN/A

Develop Information

Active CompaniesJjp Biologics Sp. z o.o.
Inactive CompaniesN/A
Active IndicationsLinear IgA Bullous Dermatosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A